Clinical Outcome Associated With Beta‐Lactam Allergy Labels in Hospitalized Patients in Belgium
Authors:
Open Access
- 27 March 2026
- journal article
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (4) , e70166
Abstract
Background: In the United States, beta‐lactam allergy labels (BLAL) are documented in 9%–16% of hospitalized patients and associated with worse clinical outcomes such as increased mortality, length of hospital stay (LOS), intensive care unit (ICU) admission, and use of alternative antibiotics, providing an incentive for broad delabeling protocols. In Europe, BLAL prevalences are lower (0.6%–5%) and the association with clinical outcomes insufficiently explored. Therefore, we assessed the association between BLAL and penicillin allergy label (PenAL) and clinical outcomes and antibiotic use in hospitalized patients in Belgium. Methods: Retrospective population‐based cohort study of all patients admitted to the University Hospitals Leuven between 2010 and 2018 for pneumonia, pyelonephritis (therapeutic indications), or appendectomy, coronary artery bypass grafting, total knee or hip replacement (prophylactic indications) or heart, kidney, liver, or lung transplantation (mixed indications). Multivariable regression analysis was performed, using BLAL or PenAL as independent variable, and age, gender, Charlson Comorbidity Index, and diagnosis as a priori hypothesized confounders. Results: We included 21,999 patients accounting for 23,842 admissions. A BLAL was recorded in 1394 (6.3%) patients, with 1113 (5.1%) having an unspecified PenAL. An increased use of next‐line antibiotics was observed among patients with BLAL or PenAL. However, BLAL or PenAL were not associated with altered in‐hospital or 3‐month post‐hospitalization mortality, LOS or ICU admission. Conclusion: Despite altered antibiotic use, we observed no association of BLAL or PenAL with clinical outcome parameters, highlighting regional differences and limiting transferability of non‐EU findings to guide EU delabeling protocols.Keywords
Funding Information
- Universitaire Ziekenhuizen Leuven, KU Leuven
- KU Leuven (C3/23/028)
- Fonds Wetenschappelijk Onderzoek (12A6Q24N)
- Fonds Wetenschappelijk Onderzoek (1805523N)
- Fonds Wetenschappelijk Onderzoek (T003023N)
This publication has 60 references indexed in Scilit:
- Self-Reported Penicillin Allergy and antibiotic use in critical care: An observational, retrospective studyAnaesthesia Critical Care & Pain Medicine, 2024
- Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin AllergyJAMA Internal Medicine, 2023
- Association of antibiotic allergy labels with hospital length of stayAnnals of Allergy, Asthma & Immunology, 2022
- Association Between Penicillin Allergy Documentation and Antibiotic UseJAMA Internal Medicine, 2020
- Is there a higher prevalence of methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE) colonization in patients with antibiotic allergy labels?American Journal of Infection Control, 2020
- Development and Validation of a Penicillin Allergy Clinical Decision RuleJAMA Internal Medicine, 2020
- Acute care beta-lactam allergy pathways: approaches and outcomesAnnals of Allergy, Asthma & Immunology, 2019
- Clinical and economic burden of hospitalizations with registration of penicillin allergyAnnals of Allergy, Asthma & Immunology, 2018
- Impact of Penicillin Allergy on Time to First Dose of Antimicrobial Therapy and Clinical OutcomesClinical Therapeutics, 2017
- Self-reported Antibiotic Allergy Incidence and Prevalence: Age and Sex EffectsThe American Journal of Medicine, 2009